Next Article in Journal
Newborn Screening Protocols and Positive Predictive Value for Congenital Adrenal Hyperplasia Vary across the United States
Next Article in Special Issue
National Program for External Quality Assessment of Chinese Newborn Screening Laboratories
Previous Article in Journal
Implementing Statewide Newborn Screening for New Disorders: U.S. Program Experiences
Previous Article in Special Issue
Use of Dried Blood Spot Specimens to Monitor Patients with Inherited Metabolic Disorders
Open AccessArticle

Assessing the Performance of Dried-Blood-Spot DNA Extraction Methods in Next Generation Sequencing

Centers for Disease Control and Prevention; 4770 Buford Hwy, NE, Atlanta, GA 30341, USA
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(2), 36; https://doi.org/10.3390/ijns6020036
Received: 26 March 2020 / Revised: 21 April 2020 / Accepted: 27 April 2020 / Published: 30 April 2020
An increasing number of newborn screening laboratories in the United States and abroad are moving towards incorporating next-generation sequencing technology, or NGS, into routine screening, particularly for cystic fibrosis. As more programs utilize this technology for both cystic fibrosis and beyond, it is critical to identify appropriate DNA extraction methods that can be used with dried blood spots that will result in consistent, high-quality sequencing results. To provide comprehensive quality assurance and technical assistance to newborn screening laboratories wishing to incorporate NGS assays, CDC’s Newborn Screening and Molecular Biology Branch designed a study to evaluate the performance of nine commercial or laboratory-developed DNA extraction methods that range from a highly purified column extraction to a crude detergent-based no-wash boil prep. The DNA from these nine methods was used in two NGS library preparations that interrogate the CFTR gene. All DNA extraction methods including the cruder preps performed reasonably well with both library preps. One lower-concentration, older sample was excluded from one of the assay evaluations due to poor performance across all DNA extraction methods. When 84 samples, versus eight, were run on a flow cell, the DNA quality and quantity were more significant variables. View Full-Text
Keywords: next generation sequencing; DNA extraction; newborn screening; dried blood spot; cystic fibrosis; CFTR next generation sequencing; DNA extraction; newborn screening; dried blood spot; cystic fibrosis; CFTR
Show Figures

Figure 1

MDPI and ACS Style

Hendrix, M.M.; Cuthbert, C.D.; Cordovado, S.K. Assessing the Performance of Dried-Blood-Spot DNA Extraction Methods in Next Generation Sequencing. Int. J. Neonatal Screen. 2020, 6, 36.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop